Search Results - "Temkin, Sarah M"

Fatty acid oxidation: An emerging facet of metabolic transformation in cancer by Ma, Yibao, Temkin, Sarah M., Hawkridge, Adam M., Guo, Chunqing, Wang, Wei, Wang, Xiang-Yang, Fang, Xianjun

“…Cancer cells undergo metabolic reprogramming such as enhanced aerobic glycolysis, mutations in the tricarboxylic acid cycle enzymes, and upregulation of de…”
Get full text

Ovarian Cancer Relies on Glucose Transporter 1 to Fuel Glycolysis and Growth: Anti-Tumor Activity of BAY-876 by Ma, Yibao, Wang, Wei, Idowu, Michael O, Oh, Unsong, Wang, Xiang-Yang, Temkin, Sarah M, Fang, Xianjun

“…The recent progresses in understanding of cancer glycolytic phenotype have offered new strategies to manage ovarian cancer and other malignancies. However,…”
Get full text

Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer by Duska, Linda R., Scalici, Jennifer M., Temkin, Sarah M., Schwarz, Julie K., Crane, Erin K., Moxley, Katherine M., Hamilton, Chad A., Wethington, Stephanie L., Petroni, Gina R., Varhegyi, Nikole E., Clift, Sheena H., Bullock, Timothy N. J., Showalter, Timothy N.

“…Background Immune checkpoint inhibitors are being considered for locally advanced cervical cancer (LACC) together with standard‐of‐care pelvic chemoradiation…”
Get full text

Chronic conditions in women: the development of a National Institutes of health framework by Temkin, Sarah M, Barr, Elizabeth, Moore, Holly, Caviston, Juliane P, Regensteiner, Judith G, Clayton, Janine A

“…Rising rates of chronic conditions were cited as one of the key public health concerns in the Fiscal Year (FY) 2021 U.S. Senate and House of Representatives…”
Get full text

Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future by Fields, Emma C, McGuire, William P, Lin, Lilie, Temkin, Sarah M

“…Ovarian cancer is the most lethal of the gynecologic cancers, with 5-year survival rates less than 50%. Most women present with advanced stage disease as the…”
Get full text

“Less is more:” The harms of overtreatment in early ovarian cancer by Temkin, Sarah M., M.D

Get full text

Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis by Fader, Amanda N., MD, Java, James, PhD, Tenney, Meaghan, MD, Ricci, Stephanie, MD, Gunderson, Camille C., MD, Temkin, Sarah M., MD, Spirtos, Nick, MD, Kushnir, Christina L., MD, Pearl, Michael L., MD, Zivanovic, Oliver, MD, Tewari, Krishnansu S., MD, O'Malley, David, MD, Hartenbach, Ellen M., MD, Hamilton, Chad A., MD, Gould, Natalie S., MD, Mannel, Robert S., MD, Rodgers, William, MD, Walker, Joan L., MD

“…Abstract Objectives We sought to analyze the clinicopathologic features, recurrence patterns and survival outcomes of women with high-grade uterine cancer (UC)…”
Get full text

Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival by Temkin, Sarah M., Miller, Eric A., Samimi, Goli, Berg, Christine D., Pinsky, Paul, Minasian, Lori

“…A mortality benefit from screening for ovarian cancer has never been demonstrated. The aim of this study was to evaluate the screening outcomes for different…”
Get full text

PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality by Yakovlev, Vasily A, Sullivan, Stephanie A, Fields, Emma C, Temkin, Sarah M

“…Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme involved in the repair of DNA single-strand breaks (SSB). The recent development of poly(ADP-ribose)…”
Get full text

Editorial: Cancer Care Delivery and Women's Health: Beyond the Patient and Provider Relationship by Temkin, Sarah M

Get full text

Perceptions of Multicancer Detection Tests Among Primary Care Physicians and Laypersons: A Qualitative Study by Samimi, Goli, Temkin, Sarah M., Weil, Carol J., Han, Paul K. J., LeeVan, Elyse, Rubinstein, Wendy S., Swigart, Tessa M., Caban, Sarah, Dent, Katherine, Minasian, Lori M.

“…ABSTRACT Introduction Multicancer detection tests (MCDs) are blood‐based tests designed to detect multiple cancer types. It is currently unclear whether these…”
Get full text

The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies by Mishkin, Grace, M.P.H, Minasian, Lori M., M.D, Kohn, Elise C., M.D, Noone, Anne-Michelle, M.S, Temkin, Sarah M., M.D

“…Abstract Objectives Enrollment of a representative population to cancer clinical trials ensures scientific reliability and generalizability of results. This…”
Get full text

Black and white women in Maryland receive different treatment for cervical cancer by Fleming, Saroj, Schluterman, Nicholas H, Tracy, J Katthleen, Temkin, Sarah M

“…Despite an overall decrease in incidence, the death rate from cervical cancer in the United States remains higher in black women than their white counterparts…”
Get full text

The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years by Gibson, Steven J, Fleming, Gini F, Temkin, Sarah M, Chase, Dana M

“…The rising number and increasing longevity of the elderly population calls for improvements and potentially a more personalized approach to the treatment of…”
Get full text

A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies by Temkin, Sarah M, Yamada, S. Diane, Fleming, Gini F

“…Abstract Objective The mTOR inhibitor, temsirolimus, has clinical activity in the treatment of gynecologic malignancies, particularly endometrial cancer. We…”
Get full text

Gynecologic Oncology and Inclusion of Women Into the Surgical Workforce: The Canary in This Coal Mine by Hong, Linda J, Rubinsak, Lisa, Benoit, Michelle F, Teoh, Deanna, Chandavarkar, Uma, Brockmeyer, Amy, Stevens, Erin, Ioffe, Yevgeniya, Temkin, Sarah M

“…Women make up a majority of the gynecologic oncology workforce. Increasing the numbers of women in leadership has been proposed as a path towards professional…”
Get full text

Oncogenic B-Myb Is Associated With Deregulation of the DREAM-Mediated Cell Cycle Gene Expression Program in High Grade Serous Ovarian Carcinoma Clinical Tumor Samples by Iness, Audra N, Rubinsak, Lisa, Meas, Steven J, Chaoul, Jessica, Sayeed, Sadia, Pillappa, Raghavendra, Temkin, Sarah M, Dozmorov, Mikhail G, Litovchick, Larisa

“…Cell cycle control drives cancer progression and treatment response in high grade serous ovarian carcinoma (HGSOC). (encoding B-Myb), an oncogene with…”
Get full text

The Current Status of Women in Surgery: How to Affect the Future by Stephens, Elizabeth H, Heisler, Christine A, Temkin, Sarah M, Miller, Pringl

“…Despite women composing half of current medical school classes, surgical specialties still struggle to attract and retain women. Even after successful…”
Get more information

Unplanned 30-day hospital readmission as a quality measure in gynecologic oncology by Wilbur, MaryAnn B, MD, MPH, Mannschreck, Diana B, BSN, Angarita, Ana M, MD, Matsuno, Rayna K, PhD, MPH, Tanner, Edward J, MD, Stone, Rebecca L, MD, MS, Levinson, Kimberly L, MD, MPH, Temkin, Sarah M, MD, Makary, Martin A, MD, MPH, Leung, Curtis A, MPH, Deutschendorf, Amy, MS, RN, Pronovost, Peter J, MD, PhD, Brown, Amy, RN, OCN, Fader, Amanda N, MD

“…Abstract Objectives Thirty-day readmission is used as a quality measure for patient care and Medicare-based hospital reimbursement. The primary study objective…”
Get full text

Inclusion of Sex and Gender to Improve the State of the Science in Women's Health by Temkin, Sarah M, Clayton, Janine Austin

“…The influence of sex and gender-related factors on health and disease at all levels of scale, across all health conditions, and throughout the entire life…”
Get full text